BioCentury
ARTICLE | Clinical News

CMX-2043: Phase IIa data

July 4, 2011 7:00 AM UTC

Top-line data from a double-blind, placebo-controlled Phase IIa trial in patients undergoing PCI showed that IV CMX-2043 demonstrated a favorable safety profile at all 3 dose levels tested, which Isch...